Neurological manifestations of SARS-CoV-2 infection are increasingly being recognized. If we focus on the coronavirus family, there is clear evidence of its neurotropic character as demyelinating disease has been previously reported with MERS (Middle East respiratory syndrome) and SARSCoV-1. Aim of the work: Is to evaluate the possible role of COVID-19 in the development of acute demyelinating CNS disorders. Material & methods: Observational Cross-sectional study of Pediatric Patients who have acute demyelinating CNS disorder, presenting to Cairo university children’s hospital over the period of 18 months from June 2020 till June 2021 with their follow-up over a period of at least 6 months till December 2021. We enrolled in our study 41 subjects who have acute demyelinating CNS disorder, 3 patients were diagnosed as Acute disseminated encephalomyelitis (ADEM), 4 as Acute necrotizing encephalopathy of childhood (ANEC), 1 as Multiphasic ADEM (MADEM), 14 as Neuromyelitis optica spectrum disorder (NMOSD), 8 as Multiple sclerosis (MS), 4 as optic neuritis (ON), and 7 as transverse myelitis (TM). the patients were evaluated clinically, radiologically and labs were done including COVID-19 antibodies (both serum IgM and IgG), that were done for the patients at their presentation and during follow-up. Results: In our study we found that 4.8% of ADEM patients, 14.3% of ANEC patients, 28.6% of NMOSD patients, 19% of MS patients, 19% of ON patients and 14.3% of TM patients were tested positive for COVID-19 immunoglobulins but with no significant statistical correlation.